title: Vulvodynia: new concepts and review of the literature.
abstract: Vulvodynia is a multifactorial chronic pain disorder that is distressing to the patient and exigent to the physician. Although the condition is common, it remains little understood, so patients remain undiagnosed and untreated or undertreated for many years. Although multiple therapies exist in the treatment of vulvodynia, few randomized controlled clinical trials have been performed. Thus, treatment should be individualized and tailored to a patient's diagnosis, symptoms, and psychosexual functioning. Patient education is also important and is facilitated by patient brochures providing assurance that vulvodynia is a real disease.
authors.affiliation: Department of Dermatology, University of Alabama at Birmingham, 35294-0009, USA. vlgroysman@yahoo.com
authors.forename: Vlada
authors.initials: V
authors.lastname: Groysman
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001676:Biofeedback, Psychology; D001905:Botulinum Toxins / Q000627:therapeutic use; D015444:Exercise; D005247:Feeding Behavior; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D053685:Laser Therapy; D010146:Pain / Q000209:etiology; D059408:Pain Management; D017773:Pelvic Floor / Q000502:physiology; D026741:Physical Therapy Modalities; D011788:Quality of Life / Q000523:psychology; D013256:Steroids / Q000627:therapeutic use; D054515:Vulvar Vestibulitis / Q000188:drug therapy / Q000601:surgery; D056650:Vulvodynia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy
chemical_list: D000927:Anticonvulsants; D000928:Antidepressive Agents; D016898:Interferon-alpha; D013256:Steroids; D001905:Botulinum Toxins